journal article·2011-04

Hybrid materials based on montmorillonite and citostatic drugs: Preparation and characterization

Ruxandra Irina Iliescu, Ecaterina Andronescu, Georgeta Voicu, Anton Ficai, Cristina Ileana Covaliu

Applied Clay Science· Volume 52· Issue 1-2
Publisher page

Abstract

Abstract The purpose of the present study is the preparation and characterization of montmorillonite/antitumor drug hybrids which can be further included in drug delivery systems (DDS) for oral chemotherapy. Materials used for obtaining montmorillonite-based complexes were sodium montmorillonite (MMT, ClNa) as the clay mineral phase and three pharmacologically active substances: one of them being hydrophobic (aminoglutethimide), the others, hydrophilic (irinotecan and carboplatin). For each of the three pharmaceuticals, the MMT/drug complex was prepared by mixing a MMT/water stable suspension with the drug solution; the resulting MMT–drug hybrid was analyzed before and after washing it with water. The experimental techniques used for characterizing the clay mineral and the hybrid materials obtained by drug intercalation into the MMT structure were: X-ray diffraction (XRD), infrared spectroscopy (FT-IR), complex thermal analysis (DTA, TG, DTG) and scanning electron microscopy (SEM). Adsorption of drugs in the MMT structure took place — both within the interlayer spacing, by replacing the water molecules, and on the surface. A part of the drug levigates and is lost during the washing step. Based on DTA/TG results, drug incorporation efficiency into the mineral clay decreases in the following order: aminoglutethimide, irinotecan and carboplatin.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Clay minerals and soil interactions · Layered Double Hydroxides Synthesis and Applications · Polymer Nanocomposites and Properties

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (24)

Show source-provided references
1. Use of clays as drug delivery systems: possibilities and limitations10.1016/j.clay.2006.06.015 ↗
2. Nature of bonding in montmorillonite adsorbates I: surface adsorption10.1002/jps.2600600515 ↗
3. Drug interactions with diosmectite: a study using the artificial stomach–duodenum model10.1016/S0378-5173(99)00073-3 ↗
4. Understanding the characteristics of l-ascorbic acid–montmorillonite nanocomposite: chemical structure and biotoxicity10.4015/S1016237206000075 ↗
5. Clay minerals and layered double hydroxides for novel biological applications10.1016/j.clay.2006.07.007 ↗
6. Dobrozski, D. J., 2000. Oral liquid mucoadhesive compositions. US Patent Appl. No.: 10/021,327.
7. Effect of montmorillonite on drug release from polymeric matrices10.1002/ardp.19893221103 ↗
8. Montmorillonite intercalated with vitamin B1 as drug carrier10.1016/j.clay.2009.06.001 ↗
9. Montmorillonite as a drug delivery system: intercalation and in vitro release of timolol maleate10.1016/j.ijpharm.2009.03.004 ↗
10. Protective effect of montmorillonite on plasmid DNA in oral gene delivery into small intestine10.1248/bpb.27.2049 ↗
11. Nature of bonding in montmorillonite adsorbates II: bonding as an ion–dipole interaction10.1002/jps.2600610321 ↗
12. Clay minerals and anionic clays
13. Effect of montmorillonite on the swelling behaviour and drug-release behaviour of nanocomposite hydrogels10.1002/app.12624 ↗
14. Effect of bentonite on the physical properties and drug release behaviour of poly(AA-co-PEGMEA)/bentonite nanocomposite hydrogels for mucoadhesive10.1002/app.13499 ↗
15. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier10.1016/S0142-9612(01)00325-8 ↗
16. Marenzi, G., Bolognese, A., Califano, L., Calignano, A., Constantino, U., Sammartino, G., Vittoria, V., 2008. Controlled-delivery system of pharmacologically active substances, preparation process and medical use thereof. USPTO Patent Appl. 20080299202.
17. In vitro adsorption of various pharmaceuticals to montmorillonite10.1002/jps.2600650623 ↗
18. Nanoclays for polymer nanocomposites, paints, inks, greases and cosmetics formulation, drug delivery vehicle and waste water treatment10.1007/BF02704606 ↗
19. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel10.1016/j.biomaterials.2009.02.045 ↗
20. Ion-exchange resins: carrying drug delivery forward10.1016/S1359-6446(01)01922-5 ↗
21. Current challenges in clay minerals for drug delivery10.1016/j.clay.2010.01.007 ↗
22. Intercalation of amido-cationic drug with montmorillonite
23. Some physicochemical properties of the montmorillonites10.1002/jps.2600551110 ↗
24. Biopolymer chitosan/montmorillonite nanocomposites: preparation and characterization10.1016/j.polymdegradstab.2005.03.001 ↗